Conclusion
To conclude, Roxadustat as a novel orally administered for the treatment
of anemia for CKD. This meta-analysis of the 17 trials with a total of
6673 patients revealed that there were no significant differences in
terms of cardiovascular events, renal-related adverse events, the risk
of progression to ESKD, or hyperkalemia using Roxadustat for treating
anemia in CKD, regardless of whether dialysis was received or not.
However, attention must be paid to the occurrence of hypertension in
patients with CKD anemia treated with Roxadustat.